(For more market insights, including options activity, click on ; for the Day Ahead newsletter link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index futures were little changed on Monday. Dow Jones industrial average futures were up 0.59 percent at 15,850, while S&P 500 futures and Nasdaq 100 futures were unchanged.
** USEC Inc, Friday close $8.81, -63.68 pct premarket
The supplier of enriched uranium for commercial nuclear power plants, said it expects to file for bankruptcy protection as part of a deal with its bondholders.
** NUPATHE INC, Friday close $2.3, +47.83 pct premarket
Endo Health Solutions Inc said it would buy NuPathe for about $105 million to gain access to migraine treatment Zecuity.
** AVAGO TECHNOLOGIES LTD, Friday close $45.65, +10.41 pct premarket
** LSI CORP, Friday close $7.91, +38.56 pct premarket
Avago, whose chips are used in Apple Inc’s products, will buy LSI for $6.6 billion in cash to enter the fast-growing storage chip market.
** SOLTA MEDICAL INC, Friday close $2.09, +39.23 pct premarket
Valeant Pharmaceuticals International said it would acquire Solta Medical for about $236 million in cash, giving it access to products used in procedures such as skin rejuvenation, skin tightening and body contouring.
** AGENUS INC, Friday close $2.44, +29.10 pct premarket
The biotechnology company said data from a mid-stage trial showed more than 90 percent of brain cancer patients treated with its experimental cancer vaccine were alive at six months after surgery.
** AERCAP HOLDINGS NV, Friday close $24.93, +34.34 pct premarket
** AMERICAN INTERNATIONAL GROUP, Friday close $49.73, +2.21 pct premarket
The U.S. insurer said it would sell its aircraft-leasing business to AerCap Holdings in a deal valued at about $5.4 billion, marking the insurer’s exit from its last non-core business.
** CUBIST PHARMACEUTICALS INC, Friday close $62.78, +11.10 pct premarket
The company said its experimental antibiotic for treating abdominal infections was found as effective as a widely used antibiotic in a late-stage trial.
** BIOLINERX, Friday close $2.55, +26.67 pct premarket
The Israel-based drug developer said initial data from a mid-stage trial of its experimental blood cancer drug showed the medicine was safe and made cancer cells more vulnerable to chemotherapy. Eight patients have already been enrolled in the study, out of a total expected 50, at eight sites in the United States and Israel.
** SPRINT CORP, Friday close $8.43, +3.56 pct premarket
** T-MOBILE US INC, Friday close $27.64, -1.05 pct premarket
Sprint Corp is mulling a takeover of smaller rival T-Mobile US and could make a bid in the first half of 2014, according to a report in The Wall Street Journal.
** HARVEST NATURAL RESOURCES INC, Friday close $3.94, +19.29 pct premarket
The oil and gas producer said it would sell its 32 percent stake in Petrodelta SA, a joint venture with Venezuela’s state-owned Petroleos de Venezuela SA, for $400 million in cash. The company said it had closed the first transaction in the sale of its assets for $125 million and it will completely exit Venezuela with a second transaction of $275 million.
** EXXON MOBIL CORP, Friday close $95.31, +1.01 pct premarket
Goldman Sachs raised its rating on the world’s largest publicly traded oil company’s stock to “buy” from “neutral,” saying the company was nearing a turning point in terms of production growth and capital intensity.
The brokerage said the stock has the potential of rising 17 percent over its raised price target of $109. The previous target was $96.
** TWITTER INC, Friday close $59, -1.95 pct premarket
Wells Fargo Securities lowered its rating on the social media company’s stock to “underperform” and SunTrust Robinson lowered to “neutral,” according to Theflyonthewall.com.
** YINGLI GREEN ENERGY HOLDING CO LTD, Friday close $4.21, +4.28 pct premarket
The solar panel maker said a consortium comprising its subsidiary Yingli Energy (China) Co Ltd, Sinohydro Corp Ltd and Hydrochina Corp won 233 megawatts of solar panel projects in Algeria. The construction will start in January and end in eight months, the company said.
** CIRRUS LOGIC, $19.59, -3.73 pct premarket
Oppenheimer cut its rating on the chipmaker’s stock to “underperform” from “perform”, according to theflyonthewall.com.
** MYRIAD GENETICS INC, Friday close $23.93, +3.22 pct premarket
The molecular diagnostics company said on Saturday that its cancer test could optimally predict drug response in patients with triple negative breast cancer, citing research data.
** HALCON RESOURCES CORP, Friday close $3.79, +3.96 pct premarket
The oil and gas producer reduced its drilling and completions budget outlook for 2014 by 14 percent to about $950 million but reaffirmed its 2014 production outlook of 38,000 to 42,000 barrels of oil equivalent per day.
** ACELRX PHARMACEUTICALS INC, Friday close $8.2, +6.83 pct premarket
The company said it has sold the European marketing rights for its experimental pain treatment, Zalviso, to German drugmaker Grunenthal GmbH for an upfront payment of $30 million. The deal will cover the European Union, certain other European countries and Australia.
AcelRx is also eligible to receive about $220 million in additional milestone payments and will retain all rights to the drug in the rest of the world, including the United States and Asia. (Compiled by Neha Dimri in Bangalore)